The phenomenology and treatment of interferon-induced depression

Jennifer Loftis, Peter Hauser

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Interferon (IFN)-α, IFN-β, and IFN-γ are currently available for the treatment of malignancies, viral infections (e.g., hepatitis C virus), multiple sclerosis (MS), and skin conditions. In addition to their therapeutic effects, IFNs commonly cause various side effects. Most common among the side effects of IFN are "flu-like" symptoms such as chills, fever, and muscle soreness. However, IFN can also cause significant neuropsychiatric side effects, particularly symptoms of depression. A literature search was conducted in order to summarize current information on (1) the frequency, characteristics, and risk factors of IFN-induced depression, (2) possible biochemical mechanisms associated with IFN-induced depression, and (3) the treatment strategies for IFN-induced depression. Review of the literature suggests that symptoms of depression induced by IFN therapy, in particular IFN-α therapy, are common and can limit the treatment utility, often necessitating discontinuation of IFN therapy or the use of psychopharmacologic agents. Depression is also a suspected side effect of therapy with IFN-β and IFN-γ; however, the association has not been as convincingly confirmed. Importantly, IFNs affect neurochemical pathways putatively involved in the etiology of depression. While these depressive side effects usually resolve after the completion of IFN therapy, they can persist or reappear with dose escalations. It is recommended that health care providers, patients and their families be informed about the potential risk of the psychiatric disturbances that can occur with IFN-α therapy. Screening and monitoring, ideally using symptom rating scales for depression, and early antidepressant treatment intervention appear necessary to optimize IFN therapy for the majority of patients.

Original languageEnglish (US)
Pages (from-to)175-190
Number of pages16
JournalJournal of Affective Disorders
Volume82
Issue number2
DOIs
StatePublished - Oct 15 2004

Fingerprint

Interferons
Depression
Therapeutics
Chills
Myalgia
Therapeutic Uses
Virus Diseases
Hepacivirus
Health Personnel
Antidepressive Agents
Multiple Sclerosis
Psychiatry
Fever

Keywords

  • Cancer
  • Cytokines
  • Depression
  • Hepatitis C
  • Interferon
  • Multiple sclerosis

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

The phenomenology and treatment of interferon-induced depression. / Loftis, Jennifer; Hauser, Peter.

In: Journal of Affective Disorders, Vol. 82, No. 2, 15.10.2004, p. 175-190.

Research output: Contribution to journalArticle

@article{f00fa149288c4e0b8693831e23154f51,
title = "The phenomenology and treatment of interferon-induced depression",
abstract = "Interferon (IFN)-α, IFN-β, and IFN-γ are currently available for the treatment of malignancies, viral infections (e.g., hepatitis C virus), multiple sclerosis (MS), and skin conditions. In addition to their therapeutic effects, IFNs commonly cause various side effects. Most common among the side effects of IFN are {"}flu-like{"} symptoms such as chills, fever, and muscle soreness. However, IFN can also cause significant neuropsychiatric side effects, particularly symptoms of depression. A literature search was conducted in order to summarize current information on (1) the frequency, characteristics, and risk factors of IFN-induced depression, (2) possible biochemical mechanisms associated with IFN-induced depression, and (3) the treatment strategies for IFN-induced depression. Review of the literature suggests that symptoms of depression induced by IFN therapy, in particular IFN-α therapy, are common and can limit the treatment utility, often necessitating discontinuation of IFN therapy or the use of psychopharmacologic agents. Depression is also a suspected side effect of therapy with IFN-β and IFN-γ; however, the association has not been as convincingly confirmed. Importantly, IFNs affect neurochemical pathways putatively involved in the etiology of depression. While these depressive side effects usually resolve after the completion of IFN therapy, they can persist or reappear with dose escalations. It is recommended that health care providers, patients and their families be informed about the potential risk of the psychiatric disturbances that can occur with IFN-α therapy. Screening and monitoring, ideally using symptom rating scales for depression, and early antidepressant treatment intervention appear necessary to optimize IFN therapy for the majority of patients.",
keywords = "Cancer, Cytokines, Depression, Hepatitis C, Interferon, Multiple sclerosis",
author = "Jennifer Loftis and Peter Hauser",
year = "2004",
month = "10",
day = "15",
doi = "10.1016/j.jad.2004.04.002",
language = "English (US)",
volume = "82",
pages = "175--190",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - The phenomenology and treatment of interferon-induced depression

AU - Loftis, Jennifer

AU - Hauser, Peter

PY - 2004/10/15

Y1 - 2004/10/15

N2 - Interferon (IFN)-α, IFN-β, and IFN-γ are currently available for the treatment of malignancies, viral infections (e.g., hepatitis C virus), multiple sclerosis (MS), and skin conditions. In addition to their therapeutic effects, IFNs commonly cause various side effects. Most common among the side effects of IFN are "flu-like" symptoms such as chills, fever, and muscle soreness. However, IFN can also cause significant neuropsychiatric side effects, particularly symptoms of depression. A literature search was conducted in order to summarize current information on (1) the frequency, characteristics, and risk factors of IFN-induced depression, (2) possible biochemical mechanisms associated with IFN-induced depression, and (3) the treatment strategies for IFN-induced depression. Review of the literature suggests that symptoms of depression induced by IFN therapy, in particular IFN-α therapy, are common and can limit the treatment utility, often necessitating discontinuation of IFN therapy or the use of psychopharmacologic agents. Depression is also a suspected side effect of therapy with IFN-β and IFN-γ; however, the association has not been as convincingly confirmed. Importantly, IFNs affect neurochemical pathways putatively involved in the etiology of depression. While these depressive side effects usually resolve after the completion of IFN therapy, they can persist or reappear with dose escalations. It is recommended that health care providers, patients and their families be informed about the potential risk of the psychiatric disturbances that can occur with IFN-α therapy. Screening and monitoring, ideally using symptom rating scales for depression, and early antidepressant treatment intervention appear necessary to optimize IFN therapy for the majority of patients.

AB - Interferon (IFN)-α, IFN-β, and IFN-γ are currently available for the treatment of malignancies, viral infections (e.g., hepatitis C virus), multiple sclerosis (MS), and skin conditions. In addition to their therapeutic effects, IFNs commonly cause various side effects. Most common among the side effects of IFN are "flu-like" symptoms such as chills, fever, and muscle soreness. However, IFN can also cause significant neuropsychiatric side effects, particularly symptoms of depression. A literature search was conducted in order to summarize current information on (1) the frequency, characteristics, and risk factors of IFN-induced depression, (2) possible biochemical mechanisms associated with IFN-induced depression, and (3) the treatment strategies for IFN-induced depression. Review of the literature suggests that symptoms of depression induced by IFN therapy, in particular IFN-α therapy, are common and can limit the treatment utility, often necessitating discontinuation of IFN therapy or the use of psychopharmacologic agents. Depression is also a suspected side effect of therapy with IFN-β and IFN-γ; however, the association has not been as convincingly confirmed. Importantly, IFNs affect neurochemical pathways putatively involved in the etiology of depression. While these depressive side effects usually resolve after the completion of IFN therapy, they can persist or reappear with dose escalations. It is recommended that health care providers, patients and their families be informed about the potential risk of the psychiatric disturbances that can occur with IFN-α therapy. Screening and monitoring, ideally using symptom rating scales for depression, and early antidepressant treatment intervention appear necessary to optimize IFN therapy for the majority of patients.

KW - Cancer

KW - Cytokines

KW - Depression

KW - Hepatitis C

KW - Interferon

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=5644300777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644300777&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2004.04.002

DO - 10.1016/j.jad.2004.04.002

M3 - Article

C2 - 15488246

AN - SCOPUS:5644300777

VL - 82

SP - 175

EP - 190

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 2

ER -